---
layout: default
title: 1 3-Bisurea Daphne Mezereum Bark Goldenseal Nitric
parent: 僅模型預測 (L5)
nav_order: 16
evidence_level: L5
indication_count: 0
---

# 1 3-Bisurea Daphne Mezereum Bark Goldenseal Nitric
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Mixture (10 Components): No Repurposing Prediction Available

## One-Sentence Summary

This submission contains a 10-component mixture (including botanical extracts, minerals, chemical acids, a bacterial species, and a protozoan parasite) that does not match any single approved drug entity in either the US FDA or DrugBank databases.
The TxGNN model returned **no predicted indications** for this entry, and the drug has **no US market authorization**.
Without a resolvable drug identity, repurposing evaluation cannot proceed at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Cannot be assessed |
| US Market Status | Not marketed (0 authorizations) |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Safety Considerations

No key warnings, contraindications, or drug interaction data are available for this entry. The mixture includes pharmacologically active substances (e.g., nitric acid, wood creosote) and biologically derived materials (Salmonella Enteritidis, Trichomonas vaginalis) that may carry safety concerns at non-homeopathic concentrations.

Please refer to the relevant product labeling or consult a compounding pharmacist before any clinical use.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The submitted drug identifier resolves to a multi-ingredient combination with no single DrugBank entry, no US market authorization, and no TxGNN predictions. The pipeline lacks the minimum inputs required to generate or evaluate a repurposing hypothesis.

**To proceed, the following is needed:**

- **Clarify drug identity**: Determine whether this is a homeopathic nosode formulation, a compounded product, or a data entry error. If homeopathic, the individual active ingredients should be evaluated separately.
- **Obtain a valid DrugBank ID**: The pipeline requires a resolvable DrugBank identifier to link to the knowledge graph and generate predictions.
- **Confirm original indication**: Without a registered therapeutic indication, the "original indication → new indication" repurposing framework cannot be applied.
- **Re-run TxGNN predictions**: Once a canonical drug entity is identified, resubmit through the TxGNN pipeline to obtain scored disease candidates.
- **Safety baseline**: Retrieve package insert or compounding formulary data to establish a minimum safety profile before any downstream evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

